Jonathan Strosberg, MD, Moffitt Cancer Center, Tampa, FL, shares updated results from the Phase III NETTER-1 study (NCT01578239) of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. Previously reported findings demonstrated a significant prolongation of progression-free survival with 177Lu-DOTATATE compared to high-dose octreotide alone. After an 18-month treatment period or at the time of disease progression, patients entered the long-term follow up phase where they could receive further anti-cancer treatment. 200 patients entered this phase, with a median follow-up of over 76 months. The final overall survival results showed a non-statistically significant improvement of 11.7 months in the 177Lu-DOTATATE arm. This result may have been impacted by the high crossover rate of 36% from the control arm to radioligand therapy after progression. No new safety signals emerged during the 5-year long-term follow-up. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting
